Immuron (IMRN) Stock Price, News & Analysis

Company Overview

Immuron Limited (NASDAQ: IMRN) is a biopharmaceutical company focused on developing and commercializing orally delivered therapeutics based on highly specific antibodies derived from hyperimmune bovine colostrum. Its approach is designed to target pathogens and disease-related factors within the gastrointestinal tract without requiring systemic absorption.

The company’s leading commercial product is Travelan, an oral antibody-based product intended to help prevent travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC). Travelan is marketed in the United States and Australia, where it is available under applicable regulatory approvals and labeling. Immuron has also investigated additional applications for its antibody platform, including candidates aimed at gastrointestinal infections and inflammatory or metabolic disorders.

Immuron is headquartered in Melbourne, Australia, and has historically conducted research, clinical development and commercialization activities in Australia and the United States. Its development programs have included IMM-124E and IMM-529, which have been studied for potential uses in conditions such as nonalcoholic steatohepatitis and Clostridioides difficile infection. The company’s activities and leadership may change as its clinical and commercial programs develop.

Key Stats

• Today's Range: $1.16 to $1.22
• 50-Day Range: $1.06 to $1.84
• 52-Week Range: $0.68 to $2.39
• Volume: 43,882 shs
• Average Volume: 6.53 million shs
• Market Capitalization: $9.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Immuron Stock Analysis - MarketRank™

Immuron scored higher than 5% of companies evaluated by MarketBeat, and ranked 887th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Immuron has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Immuron has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Immuron has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.54% of the float of Immuron has been sold short.

Short Interest Ratio / Days to Cover

Immuron has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Immuron has recently increased by 240.16%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immuron does not currently pay a dividend.

Dividend Growth

Immuron does not have a long track record of dividend growth.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: -0.09

News Sentiment

Immuron has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Immuron this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for IMRN on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immuron insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.01% of the stock of Immuron is held by insiders.

Percentage Held by Institutions

0.12% of the stock of Immuron is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/25/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMRN
• CIK: 1660046
• Web: www.immuron.com.au
• Phone: (138) 892-4854
• Fax: 6103 98227735
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.17
• Quick Ratio: 5.90

Sales & Book Value

• Annual Sales: $5.47 million
• Price / Sales: 1.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.93 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: 8,070,000
• Free Float: 7,505,000
• Market Cap: $9.36 million
• Optionable: Not Optionable
• Beta: 1.16